-+ 0.00%
-+ 0.00%
-+ 0.00%

12 Health Care Stocks Moving In Wednesday's Intraday Session

Benzinga·03/19/2025 17:06:05
Listen to the news

Gainers

  • Black Diamond Therapeutic (NASDAQ:BDTX) stock moved upwards by 29.1% to $2.17 during Wednesday's regular session. The company's market cap stands at $122.9 million.
  • Lyell Immunopharma (NASDAQ:LYEL) shares moved upwards by 23.13% to $0.6. The company's market cap stands at $175.8 million.
  • Biodexa Pharmaceuticals (NASDAQ:BDRX) shares moved upwards by 22.58% to $2.47. The market value of their outstanding shares is at $1.6 million.
  • TuHURA Biosciences (NASDAQ:HURA) shares moved upwards by 17.85% to $3.3. The company's market cap stands at $139.5 million.
  • Venus Concept (NASDAQ:VERO) stock moved upwards by 17.37% to $3.35. The company's market cap stands at $2.2 million.
  • Scienture Holdings (NASDAQ:SCNX) stock rose 16.98% to $1.86. The market value of their outstanding shares is at $16.0 million.

Losers

  • Tonix Pharmaceuticals (NASDAQ:TNXP) shares fell 19.9% to $16.45 during Wednesday's regular session. The company's market cap stands at $91.9 million. The company's, Q4 earnings came out yesterday.
  • Intensity Therapeutics (NASDAQ:INTS) stock decreased by 17.91% to $1.88. The market value of their outstanding shares is at $28.5 million. As per the press release, Q4 earnings came out 4 days ago.
  • HealthEquity (NASDAQ:HQY) stock declined by 17.54% to $83.84. The market value of their outstanding shares is at $7.2 billion. As per the press release, Q4 earnings came out yesterday.
  • Can Fite Biofarma (AMEX:CANF) stock decreased by 16.84% to $1.68. The company's market cap stands at $8.3 million.
  • OmniAb (NASDAQ:OABI) shares decreased by 15.84% to $2.69. The market value of their outstanding shares is at $324.9 million. As per the news, the Q4 earnings report came out yesterday.
  • vTv Therapeutics (NASDAQ:VTVT) stock fell 14.49% to $17.95. The company's market cap stands at $46.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.